Treatment and prevention of severe hypoglycaemia in people with diabetes: current and new formulations of glucagon.
Some therapies for diabetes increase the risk of hypoglycaemia, in particular all insulins, and insulin secretagogues including the glinides and sulfonylureas. Hypoglycaemia remains a major limiting factor to successful glycaemic management, despite the availability of prevention options such as insulin analogues, continuous glucose monitoring, insulin pumps, and dogs that have been trained to detect hypoglycaemia. Non-severe (self-treated) and severe (requiring assistance for recovery) hypoglycaemia rates are higher in people with type 1 diabetes, but those with insulin-treated type 2 diabetes are also at risk. Education and regular review are essential between people with diabetes and their caregivers and health care professionals about symptoms, prevention, and treatment. Awareness of the potential dangers of hypoglycaemia is fundamental to the optimal management of diabetes. When therapy is intensified to achieve glycaemic targets, it is important that people at risk of severe hypoglycaemia, and particularly their caregivers, have ready access to effective treatment for hypoglycaemia emergencies. The current and potential glucagon options available for treatment for severe hypoglycaemia are reviewed. This article is protected by copyright. All rights reserved.